Scientific Opinion on the substantiation of a health claim related to ProteQuine® and increasing suppressed concentrations of secretory IgA and reducing the risk of influenza and common cold pursuant to Article 14 of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 9, Issue 4, 2011, Pages

[No Author Info available]

Author keywords

common cold; health claim; influenza; ProteQuine ; secretory IgA

Indexed keywords

EID: 84974629156     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2011.2128     Document Type: Article

References (9)

1. Bártová J, Krátká Z, Benetková K, Krejsa O and Bazata V, 2001. Effect of Preventan on ScIgA levels in saliva. Praktické zubni lékarstvi, 49, 102–106.
2. Cunniffe B, Griffiths H, Proctor W, Davies B, Baker JS and Jones KP, 2011. Mucosal immunity and illness incidence in elite rugby union players across a season. Medicine & Science in Sports & Exercise, 43, 388–397.
3. Neville V, Gleeson M and Folland JP. 2008. Salivary IgA as a risk factor for upper respiratory infections in elite professional athletes. Medicine & Science in Sports & Exercise, 40, 1228–1236.
4. Podzimek S, Svobodová K, Mrklas L, Procházková J, Bártová J, Tomásová E and Hromádka R, 2007. Effect of Preventan® Akut on Secretory antibodies IgA levels in Saliva of healthy individuals. Practicus, 6, 24–25.
5. Průcha M, Zácek P, Táborsky L and Dostál M, unpublished. Using Preventan® in children after infective mononucleosis. Study report, undated.
6. Richter J, Jilek D, Král V, Vorderwinkler A, Kolinová T and Hamousová M, unpublished (a). Preliminary findings in senior population depending on Juwim (now ProteQuine®) supplementation. Study report, undated.
7. Richter J, Richterová S and Kolinová T, unpublished, (b). Findings in Preventan® supplemented child group. Study report, undated.
8. Richter R., unpublished, (c). Monitoring the influence of a six-month administration Preventan Junior® in children with a significant incidence of upper respiratory tract infections. Synopsis of study results, undated.
9. Vacková B, Hermanská Z, Skala E and Srbová D, unpublished. Supportive treatment of patients suffering from Hodgkin's disease and non-Hodgkin's lymphoms by means of preparations PREVENTAN and FORTISIM. Study report, dated 1994.